Shares of IQVIA Holdings Inc. (NYSE:IQV – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the seventeen brokerages that are covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation, thirteen have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $248.00.
Several equities research analysts recently issued reports on the stock. Mizuho raised their target price on shares of IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Barclays reiterated an “overweight” rating on shares of IQVIA in a report on Tuesday, July 28th. TD Cowen increased their target price on IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a research report on Saturday, September 12th. Finally, BMO Capital Markets upped their price target on IQVIA from $210.00 to $270.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 29th.
Check Out Our Latest Research Report on IQV
IQVIA Price Performance
IQVIA (NYSE:IQV – Get Free Report) last released its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping the consensus estimate of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The firm had revenue of $4.37 billion for the quarter, compared to the consensus estimate of $4.30 billion. During the same period in the prior year, the business posted $2.81 earnings per share. The firm’s revenue for the quarter was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Equities research analysts expect that IQVIA will post 11.56 EPS for the current year.
Insider Activity
In related news, insider Bhavik Patel sold 1,855 shares of the firm’s stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $235.27, for a total value of $436,425.85. Following the transaction, the insider owned 1,348 shares in the company, valued at approximately $317,143.96. This trade represents a 57.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Keriann Cherofsky sold 558 shares of IQVIA stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total transaction of $136,827.18. Following the transaction, the insider directly owned 2,989 shares in the company, valued at approximately $732,932.69. This trade represents a 15.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 15,581 shares of company stock worth $3,796,021. Insiders own 1.70% of the company’s stock.
Institutional Trading of IQVIA
A number of institutional investors have recently added to or reduced their stakes in IQV. Apella Capital LLC boosted its position in IQVIA by 5.1% during the 1st quarter. Apella Capital LLC now owns 1,196 shares of the medical research company’s stock valued at $211,000 after purchasing an additional 58 shares during the period. Breakwater Capital Group increased its position in IQVIA by 3.2% in the second quarter. Breakwater Capital Group now owns 2,073 shares of the medical research company’s stock worth $401,000 after buying an additional 64 shares during the period. First Growth Capital LLC lifted its stake in IQVIA by 3.2% in the first quarter. First Growth Capital LLC now owns 2,173 shares of the medical research company’s stock valued at $375,000 after buying an additional 68 shares during the last quarter. Root Financial Partners LLC boosted its holdings in shares of IQVIA by 31.0% during the fourth quarter. Root Financial Partners LLC now owns 296 shares of the medical research company’s stock valued at $67,000 after acquiring an additional 70 shares during the period. Finally, Chicago Partners Investment Group LLC grew its position in shares of IQVIA by 1.5% during the first quarter. Chicago Partners Investment Group LLC now owns 4,635 shares of the medical research company’s stock worth $812,000 after acquiring an additional 70 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.
IQVIA Company Profile
IQVIA Holdings Inc is a global provider of advanced analytics, technology solutions and contract research services for the life sciences industry. The company supports pharmaceutical, biotechnology and medical device companies throughout the product life cycle, from research and clinical development through commercialization and post-market activities.
Its offerings include clinical trial management, site and patient services, real-world evidence, healthcare data, regulatory and safety services, commercial analytics, consulting, and technology platforms.
Featured Stories
- Five stocks we like better than IQVIA
- NVIDIA Just Named AI’s Next Bottleneck—And These 3 Stocks Sit Right In It
- Gold Has Gone Sideways, But These 3 Stocks Haven’t
- The AI Bottleneck Is Not Chips Anymore and 3 Pipeline Stocks Are Cashing In
- These 3 Stocks Under $20 Have Wall Street Looking Past the Share Price
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
